Opto™ Plasma B Discovery using the Beacon® optofluidic system advances from B cells to lead molecules faster by putting function first.
In just one week, the workflow recovers 1000s of hits by screening up to 100,000 plasma B cells, down-selects lead molecules by profiling antibody function, and enables sequencing and re-expression of over 1000 functionally-characterized antibodies.
The Opto™ Plasma B Discovery workflow increases the probability of success against difficult targets, or the “high-hanging fruit,” by directly screening B cells with assays to identify functional lead molecules.
Direct functional profiling of B cells can yield up to 10-fold more hits than hybridoma campaigns against difficult membrane targets like GPCRs.
With a NanoPen™ chamber volume of only 250 picoliters, reactions are fast and precise. Complete assays in less than 1 hour, then reset your chips to enable the next assay to begin. This better characterization upfront reduces the expense of having to sequence or clone irrelevant non-functional hits.
After functional profiling, mRNA is captured on barcoded beads for on-chip cDNA synthesis. Beads are recovered in bulk to enable accurate, high-throughput sequencing and re-expression of antibody paired heavy/light chain genes.
OptoSeq™ Barcoded BCR enables linkage of sequence to function by dual optical and genetic barcoding. The genetic barcodes read by NGS sequencing can be mapped to each bead, linking every antibody sequence to its corresponding function. Amplified cDNA is cloned into expression constructs in one step using Berkeley Lights’ Opto™ BCR Rapid Re-expression kit, which enables rapid re-expression of over 1000 functionally diverse antibodies for off-chip confirmation assays.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.